Safety and efficacy of lenalidomide (Revlimid®) in recurrent ovarian and primary peritoneal carcinoma

New Guidelines to Evaluate the Response to Treatment in Solid Tumors

Patrick Therasse, Susan G. Arbuck, Elizabeth A. Eisenhauer et al. · JNCI Journal of the National Cancer Institute · 2000 · 15.7K citations

World Health Organization, Solid Tumors, Cancer Management +17

Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer

Lin Zhang, José R. Conejo-García, Dionyssios Katsaros et al. · New England Journal of Medicine · 2003 · 3.4K citations · Full text

Phase I Safety and Pharmacokinetic Study of Recombinant Human Anti-Vascular Endothelial Growth Factor in Patients With Advanced Cancer

Michael S. Gordon, Kim Margolin, Moshe Talpaz et al. · Journal of Clinical Oncology · 2001 · 915 citations

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma

Paul G. Richardson, Robert Schlossman, Edie Weller et al. · Blood · 2002 · 799 citations · Full text

Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha.

Laura G. Corral, Patrick Haslett, George W. Muller et al. · PubMed · 1999 · 731 citations

Tnf-alpha Mediates, T-regulatory Cell, Immunology +19